Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATINUM study of Plegridy patient satisfaction in relapsing-remitting multiple sclerosis
2015-002201-11Phase 4Completed
- Sponsor
- Biogen
- Start
- Sep 2016
- Modality
- Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Change from baseline in TSQM-9 convenience domain score at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
interferon beta
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2015-002201-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002201-11.